RxDoctor Payments Data

Ravi Prakash, MD

Gastroenterology · Aurora, ILNPI 1053575399

Payments from drug & device makers

$8,836in general payments, 2019–2025

Across 108 payments — averaging $81.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endogastric Solutions, Inc$2K
  • Boston Scientific$2K
  • Mauna Kea Technologies, Inc.$2K
  • Olympus Corporation Of The Americas$863
  • US Endoscopy$850
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$304
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$2,20025%
  • Speaking & faculty fees$6007%
  • Travel & lodging$1,71019%
  • Food & beverage$3,93845%
  • Education$3564%
  • Entertainment$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,836 in reported general payments places this provider in the 75th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$161,762
Medicare patients
422
Services billed
1,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$78,087
LinzessLinaclotide16$20,706
Pantoprazole Sodium351$7,671
SutabSod Sulf/Pot Chloride/Mag Sulf36$5,852
Mesalamine11$3,605
Omeprazole147$1,949
Ursodiol12$1,702
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl99$1,582
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag12$1,493
Famotidine80$1,226
Sucralfate18$824
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl49$802
Esomeprazole Magnesium11$727
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg14$198
Levofloxacin19$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$192$20,70616 claims
Braintree Laboratories, Inc.Sutab, Suflave$39$7,34548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Aurora

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →